Evidence map›Paper›PMID 31467231›Full record

ArticleCancer genomics & proteomics

Mts1 Up-regulation is Associated With Aggressive Pathological Features in Thyroid Cancer.

Min Gyeong Cheon, Ye Won Son, Joon-Hyop Lee, Ho Hee Jang, Yoo Seung Chung

Open access · diamondAbstract read
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Min Gyeong CheonDepartment of Biochemistry, College of Medicine, Gachon University, Incheon, Republic of Korea.
Ye Won SonDepartment of Biochemistry, College of Medicine, Gachon University, Incheon, Republic of Korea.
Joon-Hyop LeeDepartment of Surgery, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.
Ho Hee JangDepartment of Biochemistry, College of Medicine, Gachon University, Incheon, Republic of Korea hhjang@gachon.ac.kr dryooseung@gilhospital.com.
Yoo Seung ChungDepartment of Surgery, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea hhjang@gachon.ac.kr dryooseung@gilhospital.com.
Gachon University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThyroid cancer is the most common type of endocrine cancer and its incidence and mortality are increasing. However, few studies on the molecular factors related to its poor prognosis have been performed. The aim of our study was to identify a poor prognostic factor for thyroid cancer to reduce its overtreatment, recurrence, and mortality. MATERIALS AND

methodsThe present study is a retrospective study of 55 patients who were diagnosed with papillary thyroid cancer and operated in Korea from September 2013 to November 2015.

resultsMts1 is a member of the S100 protein family and is involved in tumor progression and metastasis. Mts1 was highly expressed in patients with thyroid cancer and high Mts1 levels were related to poor prognoses such as lymph node metastasis.

conclusionMts1 is associated with aggressive pathological features in thyroid cancer, and may be a poor prognostic factor for thyroid cancer.

Indexed as

FemaleHumansLymphatic MetastasisMaleRetrospective StudiesS100 Calcium-Binding Protein A4Thyroid Cancer, PapillaryThyroid NeoplasmsTranscriptomeUp-RegulationS100A4 protein, humanS100 Calcium-Binding Protein A4endocrine cancerMts1prognostic factorthyroid cancer

Identifiers

PMID31467231
PMCPMC6727078
OpenAlexW2970678699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.